At the news
? NEUTRALIMPACT 4/10 8-K filed May 28, 2026 at 16:01 ET
Royalty Pharma entered into a new $1.8B unsecured revolving credit facility on May 22, 2026, replacing its prior credit agreement. The facility matures on May 22, 2031, and carries financial covenants including a maximum consolidated leverage ratio of 4.00x (stepping to 4.50x post-qualifying acquisition), a maximum portfolio cash flow ratio of 5.00x, and a minimum coverage ratio of 2.50x. This refinancing extends Royalty Pharma's debt maturity profile and maintains ample liquidity for acquisitions and working capital.
- Royalty Pharma entered a $1.8B unsecured revolving credit facility on May 22, 2026.
- The facility matures on May 22, 2031 (5-year term).
- The agreement refinanced and replaced the prior $1.8B facility from September 2021.
- Financial covenants include: max consolidated leverage ratio 4.00x (4.50x step-up for qualifying acquisitions), max portfolio cash flow ratio 5.00x (5.50x step-up), min coverage ratio 2.50x.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access